Trial Profile
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2021 Status changed from active, no longer recruiting to completed.
- 02 Jan 2015 New trial record